Transition of Renal Patients Using AlloSure Into Community Kidney Care

CompletedOBSERVATIONAL
Enrollment

248

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

March 24, 2023

Study Completion Date

October 6, 2023

Conditions
Kidney Transplant Rejection
Interventions
DEVICE

AlloSure

AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8

Trial Locations (18)

10013

Chinatown Kidney, New York

11030

PRINE Health, Manhasset

11355

Nephrology Associates PC, Queens, Queens

20037

George Washington/Medical Faculty Associates Inc., Washington D.C.

22192

Mendez Center for Clinical Research, Woodbridge

24501

Lynchburg Nephrology Physicians, PLLC, Lynchburg

31201

Physician Consultants of Georgia, Macon

46804

NANI Research, Fort Wayne

60521

NANI Research, Hinsdale

63110

Washington University, St Louis

73116

Sholer Chris MD, Oklahoma City

84403

Utah Kidney Research Institute, South Ogden

91344

Amicis Research Center, Granada Hills

91345

Amicis Research Center, Mission Hills

92123

California Institute of Renal Research (Balboa), San Diego

93720

The Medical Research Group - Fresno, Fresno

94533

Amicis Research Center, Fairfield

06106

Starling Physicians, Hartford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CareDx

INDUSTRY

NCT04601155 - Transition of Renal Patients Using AlloSure Into Community Kidney Care | Biotech Hunter | Biotech Hunter